FDA approves Pfizer's LITFULO (ritlecitinib) for adults and adolescents with severe alopecia areata

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.

from Breaking World Pharma News https://ift.tt/vIFwV48